drugset / Trial / NCT05446142
A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
Phase 1
Completed
18 enrolled
Pfizer
Ono Pharmaceutical Co., Ltd. · collabPierre Fabre Laboratories · collab
RandomizedCrossoverOpen-labelOther
Summary
Relative bioavailability study to evaluate the pharmacokinetics of two new encorafenib formulations
Timeline
- Start
- 2022-07-01
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Encorafenib | Small molecule | — | — |
| Subject | Rabeprazole | Small molecule | 20 mg | — |
Indications
No indication recorded.